囊-脑室导管植入治疗胶质瘤和脑转移瘤所致占位性囊肿的疗效与安全性:一项回顾性研究
这项单中心回顾性研究纳入2010年1月至2021年12月因既往治疗的胶质瘤或脑转移瘤所致获得性占位性囊肿接受囊-脑室导管(CVC)置入的57例患者,中位年龄47岁。术后3个月70%患者症状改善,多因素分析显示囊肿出现较晚(OR 1.014)和术后囊肿体积缩小更多(OR 1.055)是症状改善的显著预测因素。作者结论认为立体定向CVC植入是有效治疗选择,但需警惕并发症和治疗失败。
要点
- 术后3个月70%的患者症状改善,局灶性神经功能缺损是最常见症状(60%)。
- 多因素分析显示囊肿出现较晚(OR 1.014;p=0.04)和术后囊肿体积缩小更多(OR 1.055;p=0.05)是症状改善的显著预测因素。
- 随访中3例出现局部囊肿复发(平均5个月,范围3-9个月),3例继发交通性脑积水和1例脑膜癌病。
核心结论
- 立体定向CVC植入是胶质瘤或脑转移瘤所致症状性占位性囊肿的有效治疗选择,与中枢神经系统WHO分级无关,但需警惕潜在并发症和治疗失败。
研究设计与样本
- 单中心回顾性研究,纳入2010年1月至2021年12月期间因既往治疗的胶质瘤或脑转移瘤所致获得性占位性囊肿接受CVC置入的所有患者,共57例,中位年龄47岁(IQR 38-63)。
主要发现
- 局灶性神经功能缺损是最常见症状(60%,n=34),其次为头痛(14%,n=8)和癫痫发作(21.1%,n=12)。
- 除1例因位置不良需翻修手术外,所有病例均实现准确CVC放置。
- CVC植入后3个月,70%的患者症状改善。
- 多因素logistic回归分析显示,疾病病程较晚出现占位性囊肿(OR 1.014;p=0.04)和术后囊肿体积缩小更多(OR 1.055;p=0.05)是CVC置入后症状改善的显著预测因素。
- 随访MRI平均5个月(范围3-9个月)发现3例局部囊肿复发;其他并发症包括3例继发性交通性脑积水和1例脑膜癌病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cysto-ventricular catheters (CVC) have emerged as promising treatment option for cystic craniopharyngioma and arachnoid cysts, but their effectiveness in treating cysts originating from glioma or brain metastasis (BM) remains limited. This study aimed to analyze the efficacy of CVC in patients with glioma and BM as well as procedure-associated morbidity. METHODS: This single-center retrospective study included all patients treated with CVC placement for acquired space-occupying cysts deriving from previously treated glioma or BMs between 1/2010 and 12/2021. RESULTS: A total of 57 patients with a median age of 47 years (IQR 38-63) were identified. Focal neurological deficits were the predominant symptoms in 60% of patients (n = 34), followed by cephalgia in 14% (n = 8), and epileptic seizures in 21.1% (n = 12). Accurate CVC placement was achieved in all but one case requiring revision surgery due to malposition. Three months after CVC implantation, 70% of patients showed symptomatic improvement. Multivariate logistic regression analysis identified the development of space-occupying cysts later in the course of the disease (OR 1.014; p = 0.04) and a higher reduction of cyst-volume postoperatively (OR 1.055; p = 0.05) were significant predictors of postoperative symptomatic improvement following CVC placement. Local cyst recurrence was observed in three cases during follow-up MRI after an average time of 5 months (range 3-9 months). Further complications included secondary malresorptive hydrocephalus in three cases and meningeosis neoplastica in one patient. CONCLUSIONS: Stereotactic implantation of CVC is an efficient treatment option for patients suffering from symptomatic space-occupying cysts from BMs or glioma, independently from their CNS WHO grade. However, a vigilant approach is crucial regarding potential complications and treatment failures.
引用
- Niedermeyer S, Terpolilli NA, Nerlinger P, et al. Efficacy and safety of cysto-ventricular catheter implantation for space-occupying cysts arising from glioma and brain metastasis: a retrospective study. Acta Neurochir (Wien). 2024. PMID: 38277007. doi:10.1007/s00701-024-05931-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。